Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate
Abrahamsen B, Grove EL, Vestergaard P
Published in Osteoporosis International
Methodology
Danish nationwide registry cohort comparing cardiovascular outcomes in strontium ranelate users versus other osteoporosis drug users.
Key Findings
Strontium ranelate users had higher baseline cardiovascular risk; no clear excess of myocardial infarction after adjustment, but overall mortality signals persisted.
Conclusions
Cardiovascular safety concerns contributed to regulatory restriction of strontium ranelate.
Limitations
Observational with confounding by indication; registry coding limitations.
Supplements Studied
Cardiovascular safety concerns contributed to regulatory restriction of strontium ranelate.
Outcomes Measured
Strontium ranelate users had higher baseline cardiovascular risk; no clear excess of myocardial infarction after adjustment, but overall mortality signals persisted.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.